Business Context and Reporting Period
Company: Ocular Therapeutix, Inc. (OCUL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: An integrated biopharmaceutical company developing therapies for retinal diseases using its ELUTYX bioresorbable hydrogel technology. Key assets include the commercial product DEXTENZA and the investigational product AXPAXLI (OTX-TKI) for wet AMD and diabetic retinopathy.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $10,785 | $10,698 |
| Net Loss | $(88,612) | $(64,053) |
| Net Loss Per Share (Basic & Diluted) | $(0.40) | $(0.38) |
| Cash and Cash Equivalents (End of Period) | $666,699 | $349,681 |
| Notes Payable (Principal) | $82,474 | $82,474 |
| Accumulated Deficit | $(1,245,635) | $(955,137) |
Operating Cash Flow: Net cash used in operating activities was $66.0 million for Q1 2026, compared to $44.7 million in Q1 2025.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased slightly by 0.8% ($87k) year-over-year, driven by a 1.4% increase in DEXTENZA product revenue ($10.8M vs $10.6M). Collaboration revenue was $0 in Q1 2026 compared to $64k in Q1 2025.
- Expense Expansion: Total operating expenses increased by $29.5 million (39.6%) to $104.1 million.
- R&D Expenses: Increased $23.4 million (54.5%) to $66.2 million, primarily due to the progression of Phase 3 trials (SOL-1, SOL-R, HELIOS-3) and a one-time cost related to transitioning injector technology.
- Selling & Marketing: Increased $2.4 million (17.2%) to $16.6 million due to pre-commercial team expansion for AXPAXLI.
- G&A Expenses: Increased $3.7 million (22.4%) to $20.0 million, driven by personnel costs and professional fees.
- Other Income: Net other income improved significantly to $4.7 million (from a loss of $0.1 million), driven by higher interest income ($6.1M vs $3.8M) and a $1.5 million gain from the change in fair value of derivative liabilities.
- Liquidity: Cash balances increased by approximately $317 million compared to the prior year period, bolstered by a $445.6 million equity offering in October 2025.
Guidance, Outlook, and Risks
Clinical and Commercial Outlook
- AXPAXLI (Wet AMD): Announced positive topline Week 52 results for the SOL-1 trial in February 2026. The product met its primary endpoint (Week 36) and a key secondary endpoint (Week 52) with statistical significance versus aflibercept. The company plans to submit an NDA based on SOL-1 data, leveraging the 505(b)(2) pathway. The SOL-R trial (non-inferiority) is ongoing with topline data expected in Q1 2027.
- AXPAXLI (Diabetic Retinopathy): The HELIOS-3 trial (NPDR) has randomized its first subject. The HELIOS-2 trial is planned but not yet initiated.
- DEXTENZA: In-market sales increased by approximately 2,000 units year-over-year. Management expects continued revenue growth in 2026, partially offset by higher gross-to-net adjustments.
Liquidity and Capital Resources
Management believes existing cash and cash equivalents ($666.7 million) are sufficient to fund operations, debt service, and capital expenditures into 2028. The company maintains a minimum liquidity covenant of $20 million under its Barings Credit Facility.
Risks and Contingencies
- Legal Proceedings: EyePoint, Inc. filed a lawsuit on March 20, 2026, alleging defamation and commercial disparagement regarding AXPAXLI. A motion for a temporary restraining order was denied on April 13, 2026; a hearing on a preliminary injunction is scheduled for May 5, 2026. No accrual has been made as the outcome is uncertain.
- Derivative Liability: The company has a $12.1 million derivative liability associated with the Barings Credit Agreement, subject to fair value fluctuations based on revenue projections.
- Regulatory Risk: Future viability depends on FDA approval of AXPAXLI and continued commercial success of DEXTENZA.
Investor Verification Checklist
- Clinical Data Validation: Verify the statistical significance and clinical relevance of the SOL-1 Week 52 topline data and the safety profile (specifically regarding uveitis/iritis) prior to NDA submission.
- Regulatory Pathway: Confirm the FDA's acceptance of the 505(b)(2) pathway and the specific data package required for the AXPAXLI NDA.
- Legal Exposure: Monitor the outcome of the EyePoint litigation and the May 5, 2026, preliminary injunction hearing.
- Revenue Quality: Analyze the trend in gross-to-net provisions (currently 54.1% of gross sales) and their impact on net revenue growth for DEXTENZA.
- Cash Burn Rate: Assess the sustainability of the current operating cash burn (~$66M/quarter) against the $666.7M cash balance to validate the runway into 2028.